Marché des dispositifs de chirurgie micro-invasive du glaucome (MIGS) au Moyen-Orient et en Afrique – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché des dispositifs de chirurgie micro-invasive du glaucome (MIGS) au Moyen-Orient et en Afrique

La chirurgie micro-invasive du glaucome est utilisée pour traiter le glaucome à angle ouvert. Au départ, pour traiter le glaucome à angle ouvert, on administrait des médicaments qui réduisaient la production d'humeur aqueuse ou augmentaient l'écoulement de l'humeur aqueuse. Pour le glaucome à angle ouvert léger à modéré, on pratiquait traditionnellement un traitement pharmacologique et au laser. Avec l'arrivée des procédures de chirurgie micro-invasive du glaucome (MIGS), de nouvelles options ont été créées pour les personnes non aptes à la chirurgie conventionnelle. L'augmentation de la population gériatrique et l'augmentation des initiatives gouvernementales pour la prévention de la cécité devraient stimuler le marché. La transition rapide des médicaments contre le glaucome vers des chirurgies mini-invasives du glaucome pourrait créer des opportunités pour le fabricant de dispositifs MIGS. Cependant, les faibles facilités de remboursement pourraient constituer un obstacle pour le marché.

La hausse de la demande en chirurgie micro-invasive est due à l'incidence croissante des maladies oculaires, à la demande croissante de chirurgies micro-invasives et à la réduction des traumatismes chirurgicaux, ce qui accroît la demande du marché au cours de la période de prévision. Cependant, le coût d'installation élevé et la pénurie de professionnels qualifiés pourraient entraver la croissance du marché de la chirurgie mini-invasive au cours de la période de prévision.

Data Bridge Market Research analyse que le marché des dispositifs de chirurgie micro-invasive du glaucome (MIGS) devrait atteindre la valeur de 103,57 millions USD d'ici 2029, à un TCAC de 25,4 % au cours de la période de prévision. Les « stents MIGS » représentent le segment technologique le plus important du marché des dispositifs de chirurgie micro-invasive du glaucome (MIGS) en raison des développements rapides des voies technologiques pour commercialiser l'utilisation des dispositifs de chirurgie micro-invasive du glaucome (MIGS). Le rapport sur le marché des dispositifs de chirurgie micro-invasive du glaucome (MIGS) couvre également en profondeur les avancées technologiques.         

Market Definition

MIGS stands for micro invasive glaucoma surgery, which helps treat glaucoma. It is a breakthrough technology in the treatment of mild to moderate glaucoma. It is an alternative to the medications given earlier, and it also prevents the complications of conventional surgery. These procedures are used to lower the intra-ocular pressure of the eye to avoid damage to the optic nerve. These procedures are safer and have a very rapid recovery time compared to conventional surgery. The various MIGS devices implanted are shunts and stents to lower the IOP.

Micro Invasive Glaucoma Surgery (MIGS) Devices Market Dynamics

• Increase in the geriatric population

A significant health-related issue among the elderly is vision loss. According to the American Academy of Family Physicians, by age 65, one in three people suffer from vision-reducing eye disease. The elderly population is increasing rapidly. Therefore this creates a demand for advanced technologies to treat glaucoma amongst older adults. Hence, an increase in the geriatric population is a driver for the market.

• Rise in incidence of glaucoma across the world

The cause of irreversible global blindness is majorly glaucoma. A glaucoma is a group of eye disorders that have very little to no symptoms in the initial stage but afterward lead to damage of optic nerves, which can lead to vision loss or blindness. The prevalence of glaucoma has been increasing. Therefore this creates a demand for MIGS devices; hence an increasing incidence of glaucoma is expected to act as a driver for the market.

• Government initiatives to increase awareness about the prevention of blindness

According to WHO, at least 2.2 billion people have visual impairment and blindness, out of which at least 1 billion have a vision impairment that could have been prevented. To prevent these, the government of several countries across the globe have taken initiatives. This creates a demand for advanced treatments such as micro-invasive glaucoma surgery, which boosts the MIGS device market. Hence, it is expected to act as a driver for the market.

• Introduction of technological advanced product 

Glaucoma is a severe eye disease that can lead to vision loss if not controlled. It generally does not lead to blindness as it can be controlled by modern treatment and many options for preventing further damage. With the increased scientific developments, there has been a revolutionary change in the treatment of glaucoma. With the advent of micro-invasive glaucoma surgery, there is a paradigm shift in medicine as it can help in the treatment of glaucoma at an early stage and avoid the dependency on filtration surgeries like trabeculectomy. This also overcomes the risks associated with these incisional surgeries. There are various advancements in the treatment of glaucoma with MIGS.

Restraints/Challenges faced by the Market

• Stringent regulations for MIGS devices

There are at least 7 regulations that any device manufacturer must completely fulfill in the U.S., namely Establishment Registration & Medical Device Listing, Premarket Notification 510(k), Premarket Approval (PMA)(only for class three devices), Investigational Device Exemption (IDE) for clinical studies, Quality System (QS) regulation, Labeling requirements, and Medical Device Reporting (MDR). These highest-risk devices need a more stringent premarket application regulatory process to demonstrate valid evidence of safety and efficacy. Lengthy timelines result in delayed access, which might restrict the market for MIGS devices.

• High cost of surgical procedures

Though glaucoma treatments have modest results and are safer than traditional filtration surgeries, they have very high costs. Also, people may require subsequent surgeries if the intra-ocular pressure is not effectively lowered at once. All these considerations make these procedures highly costly and inaccessible to most people and hence, high surgical procedure costs might be a restraint on the market.

Recent Developments

• In January 2022, Glaukos announced GLK=301's first patient enrolment in the Phase II clinical trial for dry eye disease. After the successful approval from the regulatory body, this drug will help the company grow its business segment.
• In January 2022, Alcon acquired Ivantis, developer of the novel Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device. This surgical device is designed to lower eye pressure for open-angle glaucoma patients. This acquisition will enhance the company’s portfolio in eye surgery segment.

Micro Invasive Glaucoma Surgery (MIGS) Devices Market Scope

The micro invasive glaucoma surgery (MIGS) devices market is segmented on the basis of type, product type, technology, price and application. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• MIGS stents
• MIGS shunts
• Others

On the basis of product, the micro invasive glaucoma surgery (MIGS) devices market is segmented into MIGS shunts, MIGS stents, and others.

Target

• Trabecular meshwork
• Suprachoroidal space
• Subconjunctival filtration
• Reducing aqueous production

On the basis of target, the micro invasive glaucoma surgery (MIGS) devices market is segmented into the trabecular meshwork, suprachoroidal space, subconjunctival filtration, and reducing aqueous production.

Surgery

• Glaucoma in conjunction with cataract
• Stand-alone glaucoma

On the basis of surgery, the micro invasive glaucoma surgery (MIGS) devices market is segmented into glaucoma in conjunction with cataract and stand-alone glaucoma.

End User

• Hospital outpatient departments (HOPD)
• Ophthalmology clinics
• Ambulatory surgery centers (ASCS)
• Others

On the basis of end-user, the micro invasive glaucoma surgery (MIGS) devices market is segmented into hospital outpatient departments (HOPD), ophthalmology clinics, ambulatory surgery centers (ASCS), and others.

Distribution Channel

• Direct tender
• Retail sales

On the basis of distribution channel, the micro invasive glaucoma surgery (MIGS) devices market is segmented into direct tender and retail sales.

Micro Invasive Glaucoma Surgery (MIGS) Devices Market Regional Analysis/Insights

The micro invasive glaucoma surgery (MIGS) devices market is analyzed and market size insights and trends are provided by country, product, target, surgery, end user, and distribution channel as referenced above.

The countries covered in the micro invasive glaucoma surgery (MIGS) devices market report are South Africa, Saudi Arabia, U.A.E., Israel, Egypt, and the rest of the Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

South Africa dominates the Middle East and Africa micro invasive glaucoma surgery (MIGS) devices market due to the surging cases of glaucoma and eyes diseases which is expected to boost the market growth.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Micro Invasive Glaucoma Surgery (MIGS) Devices Market Share Analysis

Le paysage concurrentiel du marché des dispositifs de chirurgie micro-invasive du glaucome (MIGS) fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence régionale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché des dispositifs de chirurgie micro-invasive du glaucome (MIGS).

Certains des principaux acteurs opérant sur le marché des dispositifs de chirurgie micro-invasive du glaucome (MIGS) sont AbbVie, BVI, Ellex, Glaukos Corporation, Johnson and Johnson, Alcon, Microsurgical technology, New World Medical, Santen Pharmaceutical, Nova Eye Medical Limited, Belkin Vision et Sight Scientific, entre autres.

SKU-53735